Inhaled Product Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inhaled Product Characterization
The authors discuss the analysis of the resulting data, focusing on methods for the calculation of mass median ærodynamic diameter, one of the metrics routinely used for comparative testing.


Pharmaceutical Technology
pp. s33-s37

References

1. Stimuli to the Revision Process, "Generalized Simplified Approaches for Mass Median Aerodynamic Determination," Pharmacopeial Forum 36 (3) (2010).

2. M. Copley and J. McDonald, Inhalation 3 (11), 14–17 (2009)

3. W.C. Hinds, Aerosol Technology, Properties, Behavior, and Measurement of Airborne Particles (John Wiley & Sons, 2nd ed., 1999).

4. T.K. Church et al., Proc. Respiratory Drug Deliv. XII, 2, 509–509–512 (2010).

5. D.J. Finney, Probit Analysis (Cambridge University Press, Cambridge, 1971).

6. USP 34–NF 29, Physical Tests and Determinations <601> "Aerosols, Nasal Sprays, Metered-dose Inhalers, and Dry Powder Inhalers," pp. 237–239.

7. D. Lewis, Inhalation (August 2008).

8. Inhalation Report, "How do you calculate MMAD," (2010), http://www.inhalationreport.com/, accessed 10 Oct. 2011.

9. Tougas et al., AAPS Pharm. Sci. Technol., 10 (4) 1276–1285 (2009)

10. Proceedings of EPAG AIM Workshop at DDL 21 (Edinburgh International Conference Center, Dec. 8–10, 2010).

11. P.N. Pantelides et al., proceedings of RDD Europe (Berlin, 2011), pp. 391–395.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here